A037 Impact of the CYP2C19*17 allele on platelet response to clopidogrel in patients suffering from non–st elevation acute coronary syndrome  by Frere, C. et al.
S20 Abstracts
in vitro suggèrent fortement l’implication de SYK dans cette 
phosphorylation.
En parallèle, dans le cadre d’une étude sur la polyarthite rhumatoide, 
nous avons mis en évidence la présence d’une forme circulante de 
VE-cadhérine correspondant à son domaine extracellulaire clivé. 
Cette étude a pour but d’évaluer si la VE-cadhérine circulante peut 
être un marqueur d’une in ammation à distance. Les résultats sur 
75 patients, en cours d’analyse statistique, seront exposés dans 
cette présentation.
La VE-cadhérine, tant par sa phosphorylation que par sa 
présence dans les  uides biologiques, pourrait être une signature 
de l’endothélium activé (phosphorylation) et/ou agressé 
(protéolyse).
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Objectives — The aim of the study was to evaluate the impact 
of CYP2C19*17 on Platelet Response to Clopidogrel in patients 
suffering from Non-ST Elevation Acute Coronary Syndrome (NSTE 
ACS).
Background — Clopidogrel is activated by cytochrome P450 (CYP) 
to generate an active metabolite that inhibits platelets through 
irreversible binding to the platelet P2Y12 receptor. We have 
shown that CYP2C19*2 is associated with a low platelet response 
to clopidogrel (Am J Cardiol 2008), which has been demonstrated 
to predict adverse events in patients suffering from NSTE ACS. 
Recently, a novel allelic variant (CYP2C19*17) encoding an 
ultrarapid enzyme activity has been described.
Results — We evaluated in 449 patients with non-ST elevation ACS 
after the administration of a loading dose of 600 mg clopidogrel, 
the impact of CYP2C19*17 on platelet response to clopidogrel 
assessed by vasodilator stimulated phosphoprotein phosphorylation 
index (PRI VASP). No signi cant deviations from Hardy-Weinberg 
equilibrium were observed for this genetic variant. The observed 
frequency of the CYP2C19*17 allele was 20 %. The CYP2C19*17 allele 
was signi cantly associated with VASP, both in recessive (p =0.02) 
and codominant (p =0.0073) models. The CYP2C19*17 allele carriers 
(extensive metabolizers) exhibited the lowest PRI VASP (mean ± SD 
= 49.7±23.7 vs 55.9±22.8), testifying a better platelet response to 
clopidogrel. The interaction between the CYP2C19*2 (decrease in 
platelet response to clopidogrel) an the CYP2C19*17 allele (increase 
in platelet response to clopidogrel) was not signi cant.
Conclusion — The present data suggest that the CYPC19*17 allele 
in uences platelet response to clopidogrel in patients with NSTE 
ACS, independently from the CYPC19*2 allele.
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Aims: Diabetic patients have a higher prevalence of inadequate 
platelet response to Clopidogrel. However, determinants of this 
low response remain uncertain.
Methods and Results — We analyzed ADP-induced platelet 
aggregation (ADP-Ag), and Platelet Reactivity Index of Vasodilatator-
Stimulated Phosphoprotein (PRI VASP) in 124 diabetic patients 
treated with Clopidogrel, and repeated them after glycemic 
optimization in 15 uncontrolled patients.
Platelet tests did not correlate with glycemic control and did not 
change after glycemic optimization. Type 2 diabetics had higher 
ADP-Ag and PRI VASP than type 1 (49±19 vs 33±19 %, p = 0.008 ; 
62±16 vs 48±27 %, p = 0.02, respectively). On adjustment for studied 
variables ADP-Ag but not PRI VASP remained statistically associated 
with the type of diabetes (p = 0.007 ; p=0.11 respectively). Also 
 brinogen was an independent predictor of ADP-Ag and clopidogrel 
non responders had elevated plasma  brinogen, compared with 
responders: 8.2 ± 0.5 versus 3.8 ± 0.1 g/L (p<10-4). A threshold of 
3.57 g/L led to a negative predictive value of 94.7 %.
Conclusion — Platelet response to clopidogrel, mainly ADP-Ag 
was not related to glycemic control but to the type of diabetes. 
Moreover  brinogen strongly predicted ADP-Ag in diabetics.
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Introduction — Proprotein convertase subtilisin kexin type 9 (PCSK9) 
is a natural inhibitor of the low density lipoprotein receptor (LDLr) 
and its de ciency confers a high protection against cardiovascular 
diseases. We previously reported that PCSK9 expression is regulated 
by nutritional status and insulinemia.
Objectives — Here, we investigated the metabolic adaptation 
of PCSK9 de cient mice (PCSK9-/-) in response to a high fat diet 
(HFD).
Methods & Results — PCSK9-/- and PCSK9+/+ males were given 
a 60 % fat diet for 10 weeks. Before treatment, both genotypes 
responded similarly to oral glucose tolerance (OGTT) and insulin 
tolerance test (ITT). The  rst week following HFD feeding, we 
noticed an initial rise in glycemia for both genotypes (32 and 37.8 %), 
re ecting diet-induced insulin resistance. Despite comparable 
OGTT and ITT, PCSK9-/- mice presented a slight reduction of blood 
